With enough patient support, cancer care disparities vanish
from MedPage Today
Substandard therapy and outcomes are not inevitable for patients with socioeconomic disadvantages, a researcher said — and showed data from his own safety-net cancer center to prove it. Nonwhite patients with diffuse large B cell lymphoma were just as likely as whites to receive standard-of-care therapies and be entered into clinical trials, and nonwhites showed the same two-year rates of progression-free survival. Moreover, nonwhite patients were nearly twice as likely to undergo stem cell transplant, a therapy that tends to be less commonly provided to nonwhite patients relative to Caucasians.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063